10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-PI3 Kinase, p85 (C-terminal region) Antibody

Catalog # AN1903

Product Information

Application	WB, ICC
Primary Accession	P27986
Host	Mouse
Clonality	Mouse Monoclonal
Isotype	IgG2a
Clone Names	M253
Calculated MW	83598

Additional Information

Gene ID	5295
Other Names	PI3K
Dilution	WB~~1:1000 ICC~~N/A
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Anti-PI3 Kinase, p85 (C-terminal region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Shipping	Blue Ice

Background

Phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol (PI), PI-4-phosphate and PI-4,5-bisphosphate to catalyze the production of PI-3,4,5-triphosphate. Growth factors and hormones activate PI3K to coordinate various cellular events, such as cell growth, cell cycle entry, cell migration and cell survival. This PI3K activation is reversed by PTEN. In cancers caused by the loss of PTEN activity, PI3K is constituitively active and promotes cell proliferation. PI3Ks are composed of a catalytic subunit and a regulatory subunit. Various isoforms of the catalytic subunit (p110a, p110b and p110d) associate with regulatory subunits (p85a and p85b) with the exception of p110g which interacts with a unique p101 regulatory subunit.

Images

Western blot image of human A431 cells. The blots were probed with mouse monoclonal anti-PI3 Kinase, p85 (C-terminal region) at 1:1000 (lane 1), 1:2000 (lane 2), and 1:4000 (lanes 3).





Immunocytochemical labeling of PI3 Kinase p85 in aldehyde-fixed and NP-40-permeabilized A431 cells. The cells were labeled with mouse monoclonal PI3 Kinase p85 (C-terminal region) antibody (AN1903), then the antibody was detected using appropriate secondary antibody conjugated to DyLight® 594.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.